GlassScriptPhysician profile
Louis Hiotis
NPI 1710980339
$3,396.21
in general payments reported to CMS, 2019-2025
28 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,705 · 2020: $348 · 2021: $61.38 · 2022: $236 · 2023: $356 · 2024: $447 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $580.03 | 2019-2024 | |
| Novo Nordisk INC | $557.98 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $305.17 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $284.56 | 2019-2022 | |
| Amgen INC. | $255.50 | 2019-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $228.70 | 2019-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $158.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $115.60 | 2019-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $112.73 | 2019-2020 | |
| Csl Behring | $108.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $91.46 | 2019 | |
| Lilly USA, LLC | $87.39 | 2019-2024 | Zepbound |
| Gilead Sciences, INC. | $83.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.94 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.77 | 2019-2020 | |
| Abbvie INC. | $36.71 | 2019 | |
| Ethicon US, LLC | $33.02 | 2019 | |
| Seqirus USA INC | $31.78 | 2019-2020 | |
| Abbott Laboratories | $27.77 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $26.48 | 2025 | Neffy |
| Medtronic USA, INC. | $17.67 | 2019 | |
| Radius Health, INC. | $17.44 | 2019 | |
| Kaleo, INC. | $16.30 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.86 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Hiotis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.